- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03668015
Xylitol and Sorbitol Effects on the Oral Microbiome
Xylitol and Sorbitol Effects on the Microbiome of Saliva and Plaque
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Subjects: Study protocols were approved by the Ethics Committees of the UWI, St. Augustine. Thirty healthy volunteers from The University of the West Indies (UWI), St. Augustine, Trinidad were enrolled in the study. To be eligible, subjects must have had at least 20 teeth, provided written informed consent and been willing to comply with study procedures. Subjects with systemic, infectious or inflammatory diseases or taking medicines, antibiotics or fluoride in the last month, habitual consumers of xylitol / sorbitol-containing products and mouth rinses, with abnormal salivary flow (<1ml / min), pregnant, on contraceptive pills, or with abnormal dietary habits were excluded. Consent obtained at the initial visit was verified at the second visit, prior to sample collection. The subjects were examined in the dental chair after thorough medical and dental histories were recorded. The clinical examination involved examination of the soft tissues and then dental hard tissue charting for presence of decayed, missing or filled teeth. No radiographs were used. The presence of untreated dental caries or periodontitis were not used as exclusion criteria. The decayed, missing, and filled teeth for each individual at the initial visit was documented for calculation of the index of decayed-missing-filled permanent teeth (DMFT) score.
Chewing gums: Xylitol gum (Epic Spearmint; 1.5g/pellet) designated Gum X contains 70% xylitol in addition to gum base, natural flavors, soy lecithin, gum arabic, titanium dioxide, carnuba wax. Gum S (Eclipse Spearmint), was similar except that xylitol was replaced by 63% sorbitol and 2% maltitol and aspartame was included. Gums were packed in colour-coded containers. Codes were kept confidential from the participants and researchers who interacted with them until study completion.
Study design: This prospective cross-over, double-blind, randomised study lasted 14 weeks (March - June, 2015). Throughout, subjects were instructed not to use mouthwashes or xylitol products, to consume a normal diet, continue their usual tooth brushing and to report use of antimicrobial medications. Subjects reporting the latter were dropped.
Subjects were randomly allocated to two groups, A and B (see Figure 1). Both groups entered a 4-week "washout period" during which no gum was chewed, followed by a 3-week treatment period (treatment period 1) during which Group A used Gum X and Group B used Gum S (2 gum pieces, 3 times daily after meals for 6 minutes). Both groups then underwent another 4-week washout period before entering treatment period 2 during which Group A used Gum S and Group B used Gum X for 3 weeks.
Sample collection: Saliva and plaque were collected from participants immediately before and after each treatment period (Figure 1). Subjects were instructed not to brush their teeth or use any other oral hygiene procedures at least 24 hours before sample collection, and not to eat or drink at least 1 hour before. For saliva collection, subjects chewed sterile paraffin wax and whole saliva produced was collected for 5 minutes in sterile tubes. The subject was asked to drool into the labelled 50ml collection tube (Falcon sterile, conical polypropylene tube with flat-top screw cap). This process was repeated multiple times in order to collect larger volumes of saliva (2-5 ml). The saliva was transferred via sterile pipettes into labelled sterile centrifuge tubes which were stored at -70˚C until use.
Supragingival plaque was collected with a curette from 2 molars (#16 and #36), 2 premolars (#24 and #44), and 2 incisors (#21 and #41); Plaque collection involved using a Gracey curette to remove all of the supragingival plaque from the buccal surface of the selected index tooth with as many strokes as necessary. The curette tip was immersed in the sterile DNase-free Tris-EDTA (TE) buffer in the centrifuge tube for 4-5 seconds. The face of the curette was wiped on the inside edge of the collection tube and then wiped off with sterile gauze so as to not let the buffer on the tip go into patient's mouth. The site was then immediately sampled again using the same procedure. The lid on the tube was replaced and then the tube shaken for 4-5 seconds in an attempt to maximize dispersion of the specimen in the fluid. The tube was immediately placed on ice in a Ziploc bag and stored at -70˚C until use. Samples were labelled by group (A/B), treatment period (1/2), gum used (X/S in the case of those samples collected at the end of a given treatment period) and type (saliva (s) or plaque (p)). Samples (n=232) were then shipped on dry ice to the J. Craig Venter Institute (JCVI) USA, La Jolla campus for DNA extraction and sequencing.
DNA extraction: Samples were thawed at 4˚C and vortexed thoroughly prior to DNA extraction from 500ul of saliva or plaque suspension using bead beating Lysing Matrix B tubes (MPBio Inc.), then lysozyme digest, phenol/chloroform isoamyl alcohol extraction and ethanol precipitation. Precipitated DNA was resuspended in 1x TE buffer.
Library Preparation and Sequencing: DNA from each sample was quantified using a Nanodrop spectrophotometer (Thermo Fisher Scientific, Inc, Waltham, MA). Amplicons were generated using adaptor and barcode ligated polymerase chain reaction (PCR) primers targeting the V4 region of the 16S rDNA gene (16S) and purified using Qiaquick PCR purification kits (Qiagen, Inc) following manufacturer's instructions. Purified amplicons were quantified using SybrGold (Thermo Fisher Scientific, Inc, Waltham, MA), normalized to ensure equimolar quantities of each sample, and pooled in preparation for Illumina MiSEQ sequencing. The 16S library pool was sequenced using the Illumina MiSEQ dual index 2x250bp V2 chemistry kit according to manufacturer's specifications.
16S RNA sequence data processing: Sequences for each sample were binned according to corresponding dual indices and exported as individual .fastq files using CASAVA v1.8.2 (Illumina Inc. La Jolla, CA). Sequences were processed to ensure that only quality sequences were retained, as stringent settings were kept to ensure no barcode mismatches were permitted during demultiplexing. Processed sequences were applied to the Infernal pipeline [35] for additional quality control (QC) checks. Bacterial sequences were taxonomically assigned based on the Genomic-based 16S ribosomal RNA Database (GRD; http://metasystems.riken.jp/grd/).
Statistical analyses. Distribution by age, sex and DMFT score for subjects in groups A and B were compared using independent-samples T- test, Pearson's Chi-Squared test and Wilcoxon rank sum test respectively, with a cut-off of p <0.05. To avoid possible sequence errors, operational taxonomic unit (OTU) count tables were filtered such that OTUs present in fewer than 0.1% in all samples were discarded. OTU tables were then transformed to relative abundances before community analyses were performed using the R statistical computing language (Cite R). Kruskal-Wallis test was used to assess statistical significance in microbial community composition across treatments. Wilcoxon test was used for pairwise comparison.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
To be eligible, subjects must have been 18 years and over, have had at least 20 teeth, provided written informed consent and been willing to comply with study procedures
Exclusion Criteria:
Subjects with systemic, infectious or inflammatory diseases or taking medicines, antibiotics or fluoride in the last month, habitual consumers of xylitol / sorbitol-containing products and mouth rinses, with abnormal salivary flow (<1ml / min), pregnant, on contraceptive pills, or with abnormal dietary habits were excluded
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A (Xylitol then sorbitol gum)
Subjects were randomly allocated to a group and entered a 4-week "washout period" during which no gum was chewed, followed by a 3-week treatment period (treatment period 1) during which Group A used Xylitol gum.(2 gum pieces, 3 times daily after meals for 6 minutes).Then underwent another 4-week washout period before entering treatment period 2 during which Group A used Gum Sorbitol
|
Xylitol gum contains 70% xylitol in addition to gum base, natural flavors, soy lecithin, gum arabic, titanium dioxide, carnuba wax.
Sorbitol gum was similar except that xylitol was replaced by 63% sorbitol and 2% maltitol and aspartame was included.
|
Experimental: Group B (Sorbitol then xylitol gum)
Subjects were randomly allocated to a group and entered a 4-week "washout period" during which no gum was chewed, followed by a 3-week treatment period (treatment period 1) during which Group B used sorbitol gum.
Group B used Gum Sorbitol (2 gum pieces, 3 times daily after meals for 6 minutes).Then underwent another 4-week washout period before entering treatment period 2 during which Group B used Gum xylitol
|
Sorbitol gum was similar except that xylitol was replaced by 63% sorbitol and 2% maltitol and aspartame was included.
Xylitol gum contains 70% xylitol in addition to gum base, natural flavors, soy lecithin, gum arabic, titanium dioxide, carnuba wax.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Oral microbiome composition
Time Frame: 14 weeks
|
Profile microbial communities of saliva and plaque based high-throughput sequencing of the 16S rRNA gene.
|
14 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Reisha Rafeek, MSc, BDS, The University of the West Indies
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CRP.3.MAR14.7
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Human Microbiome
-
University of AarhusAarhus University Hospital; University of Copenhagen; Arla FoodsActive, not recruitingBreast Milk Collection | Infant Gut Microbiome | Human Milk/Breastfeeding | Human Milk MicrobiomeDenmark
-
Integrative Skin Science and ResearchVerdure SciencesCompletedHuman MicrobiomeUnited States
-
Seoul National University HospitalCompletedHuman MicrobiomeKorea, Republic of
-
VA Office of Research and DevelopmentCompletedHuman MicrobiomeUnited States
-
NYU Langone HealthWithdrawn
-
University Medical Center GroningenCompleted
-
Integrative Skin Science and ResearchMicrobiome labsNot yet recruitingHuman MicrobiomeUnited States
-
DaniscoReprocell Inc; SerologixCompletedHuman MicrobiomeUnited States
-
Integrative Skin Science and ResearchSytheon Ltd.CompletedHuman MicrobiomeUnited States
-
Seoul National University HospitalCompletedHuman MicrobiomeKorea, Republic of
Clinical Trials on Xylitol then Sorbitol gum
-
Kuwait UniversityUniversity of Turku; University of MichiganCompleted
-
Baylor College of MedicineUniversity of Washington; Fogarty International Center of the National Institute... and other collaboratorsNot yet recruiting
-
Baylor College of MedicineCompletedPreterm Birth | Periodontal Disease | Caries, DentalUnited States
-
Università degli Studi di SassariUniversity of MilanCompletedPeriodontal Diseases | Dental CariesItaly
-
Roquette Management (Shanghai) Co., Ltd.Kaunas University of Medicine; West China College of StomatologyCompletedRe-mineralizationChina
-
University of WashingtonRecruitingNeurodevelopmental Disorders | PrematurityMalawi
-
Universidad de CuencaRecruiting
-
University of TartuUniversity of TurkuUnknown
-
University of TurkuChr Hansen; Fennobon oy, Karkkila, Finland (provides the tablets for the pacifier) and other collaboratorsCompletedDental Caries | Infectious DiseasesFinland
-
Unity Health TorontoThe Hospital for Sick ChildrenUnknownDental Caries in Children | Acute Otitis Media | URTICanada